Aegerion Pharmaceuticals, Inc.  

(Public, NASDAQ:AEGR)   Watch this stock  
Find more results for AEGR
+0.36 (1.47%)
Jan 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 23.78 - 25.00
52 week 19.10 - 68.76
Open 24.45
Vol / Avg. 813,029.00/725,345.00
Mkt cap 707.20M
P/E     -
Div/yield     -
EPS -1.54
Shares 28.44M
Beta 0.86
Inst. own 142%
Feb 24, 2015
Q4 2014 Aegerion Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 12, 2015
Aegerion Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 12, 2015
Aegerion Pharmaceuticals Inc at JPMorgan Healthcare Conference
Jan 12, 2015
Preliminary 2014 Aegerion Pharmaceuticals Inc Net Product Sales
Dec 2, 2014
Aegerion Pharmaceuticals Inc at Deutsche Bank BioFEST
Nov 6, 2014
Aegerion Pharmaceuticals Inc Acquires Myalept(TM) From AstraZeneca Conference Call
Oct 30, 2014
Q3 2014 Aegerion Pharmaceuticals Inc Earnings Call
Oct 30, 2014
Q3 2014 Aegerion Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -13.44% -130.51%
Operating margin -4.55% -128.43%
EBITD margin - -127.45%
Return on average assets -8.70% -55.72%
Return on average equity -17.57% -73.06%
Employees 217 -
CDP Score - -


1 Main St Ste 800
CAMBRIDGE, MA 02142-1531
United States - Map
+1-617-5007867 (Phone)
+1-617-9457968 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company�s first product, lomitapide, received marketing approval, under the brand name Juxtapid capsules, from the United States Food and Drug Administration as an adjunct to a low-fat diet and other lipid-lowering treatments in adult patients with homozygous familial hypercholesterolemia (HoFH). The Company launched Juxtapid in the United States in January 2013 and received marketing authorization for lomitapide in the European Union, under the brand name Lojuxta hard capsules in July, 2013. Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada. It sells lomitapide, on a named patient basis, in Brazil and in a limited number of other countries outside the United States and the European Union where such sales are authorized based on the regulatory approval.

Officers and directors

David I. Scheer Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Marc D. Beer Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Mark J. Fitzpatrick Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Carolina Alarco President, International
Bio & Compensation  - Reuters
Craig Fraser Chief Operating Officer,
Age: 50
Bio & Compensation  - Reuters
Anne Marie Cook Senior Vice President, General Counsel, Secretary
Age: 49
Bio & Compensation  - Reuters
Martha J. Carter Senior Vice President, Chief Regulatory Officer
Age: 61
Bio & Compensation  - Reuters
Mark Sumeray M.D. Chief Medical Officer
Age: 48
Bio & Compensation  - Reuters
Sol J. Barer Independent Director
Age: 67
Bio & Compensation  - Reuters
Antonio M. Gotto Jr., M.D., Independent Director
Age: 78
Bio & Compensation  - Reuters